Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.9% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price dropped 0.9% during mid-day trading on Wednesday . The stock traded as low as $6.39 and last traded at $6.55. Approximately 974,966 shares changed hands during trading, a decline of 83% from the average daily volume of 5,726,458 shares. The stock had previously closed at $6.61.

Analyst Ratings Changes

RXRX has been the subject of several recent analyst reports. Needham & Company LLC dropped their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Jefferies Financial Group cut their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Stock Up 1.9 %

The company has a market capitalization of $1.82 billion, a P/E ratio of -4.03 and a beta of 0.80. The company has a 50 day simple moving average of $6.72 and a two-hundred day simple moving average of $7.73. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.38) earnings per share. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,606,442.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $6.82, for a total value of $78,068.54. Following the completion of the sale, the director now directly owns 7,144,216 shares in the company, valued at $48,723,553.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 195,682 shares of company stock worth $1,284,153 over the last 90 days. Company insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RXRX. Green Alpha Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after buying an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC boosted its stake in Recursion Pharmaceuticals by 7.3% in the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares in the last quarter. Amalgamated Bank grew its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new position in Recursion Pharmaceuticals in the first quarter worth $26,000. Finally, Victory Capital Management Inc. increased its position in shares of Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.